![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Approves New Indication for Merck's Hyzaar
FDA Approves New Indication for Merck's Hyzaar
The FDA has approved a new indication for Merck's Hyzaar, a fixed-dose combination antihypertensive drug.
Hyzaar (losartan potassium-hydrochlorothiazide) is now indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (LVH).
In March 2003, the FDA approved the same indication for Merck's antihypertensive drug Cozaar (losartan potassium tablets). Hyzaar and Cozaar are currently the only angiotensin II receptor blockers to be indicated to reduce the risk of stroke in patients with hypertension and LVH.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct